Alexion Pharmaceuticals (ALXN) was Upgraded by Citigroup to ” Buy”. Earlier the firm had a rating of “Neutral ” on the company shares. Citigroup advised their investors in a research report released on Jun 27, 2016.
Many Wall Street Analysts have commented on Alexion Pharmaceuticals. Company shares were Reiterated by Barclays on May 9, 2016 to “Equal Weight”, Firm has raised the Price Target to $ 180 from a previous price target of $175 .
On the company’s financial health, Alexion Pharmaceuticals reported $1.11 EPS for the quarter, missing the analyst consensus estimate by $ -0.02 based on the information available during the earnings call on Apr 28, 2016. Analyst had a consensus of $1.13. The company had revenue of $701.00 million for the quarter, compared to analysts expectations of $711.95 million. The company’s revenue was up 16.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.28 EPS.
Alexion Pharmaceuticals closed down -10.58 points or -8.56% at $112.99 with 75,14,338 shares getting traded on Friday. Post opening the session at $117.5, the shares hit an intraday low of $110.56 and an intraday high of $119.51 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
In a different news, on Jun 14, 2016, John B Moriarty (EVP & General Counsel) sold 918 shares at $135.72 per share price. According to the SEC, on May 18, 2016, Martin Mackay (EVP & Global Head of R&D) sold 4,097 shares at $139.81 per share price. On May 13, 2016, Heidi L Wagner (SVP, Global Government Affairs) sold 53 shares at $138.65 per share price, according to the Form-4 filing with the securities and exchange commission.
Alexion Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. As of June 23 2015 the Company had eight product candidates in clinical trials for 11 indications. The Company’s product pipeline includes complement inhibitor portfolio metabolic rare disease portfolio and preclinical candidates. Its complement inhibitor portfolio includes Soliris ALXN1007 ALXN1210 and ALXN5500. Its metabolic rare disease portfolio includes Strensiq Kanuma ALXN1101 and SBC-103. The Company’s preclinical candidates include mRNA Therapies SBC-105 and other complement inhibitors. Its Soliris is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) two life-threatening ultra-rare disorders.